The Netherlands Institute for Health Services Research and SDI, a US private-sector health care information company, have formed the European Pediatric Influenza Analysis group, created to generate data needed to inform the decision process about pediatric influenza vaccination policy in individual European countries. Researchers from Denmark, England, Finland, Italy, the Netherlands, Scotland, Spain and Wales are participating; it is hoped that other countries will also join.
The EPIA was formed to address knowledge gaps highlighted in a recent European Center for Disease Prevention and Control (ECDC) report that concluded that a key barrier to decision-making about pediatric flu vaccines is the lack of high-quality, European-specific data on disease burden, especially for young children. It is estimated by the ECDC that at least 40,000 people die each year from influenza in the European Union. The EPIA will present the initial results from their research project at the 27th annual meeting of the European Society for Pediatric Infectious Diseases in June.
In the 2006 European Journal of Pediatrics article, titled Should healthy children be vaccinated against influenza?, Terho Heikkinen and colleagues noted: "in many European and other countries, the discussion about potential expansion of target groups for annual influenza vaccination has just started...the development of new vaccination strategies in any country will require careful evaluation of the benefits and disadvantages of the intervention with respect to local factors."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze